What is the price of Scilex Holding Company (SCLX)

The price of Scilex Holding Company (SCLX) is $5.61

What is the market cap of Scilex Holding Company (SCLX)

The market cap of Scilex Holding Company (SCLX) is $47.65M

Scilex Holding Company (SCLX) P/S Ratio

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Year	P/S Ratio	Change
Not enough data for the provided dates.

Year

P/S Ratio

Change

Not enough data for the provided dates.

Company	P/S Ratio	P/S Ratio Difference	Country
Eli Lilly and Company LLY.US	13.95	-	US
Johnson & Johnson JNJ.US	6.41	-	US
AbbVie Inc. ABBV.US	6.85	-	US
Roche Holding AG RO.SW	4.66	-	CH
Merck & Co., Inc. MRK.US	5.05	-	US

Company

P/S Ratio

P/S Ratio Difference

Country